A Study of DS-1103a and Trastuzumab Deruxtecan (T-DXd) in People With Solid Tumor Cancer

Full Title

A Phase 1, 2-part, Multicenter, First-in-human Dose-escalation and Dose-expansion Study of DS-1103a Combination Therapy in Subjects with Advanced Solid Tumors (DS-1103A COMBINATION THERAPY FIRST-IN-HUMAN STUDY)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Nicholas Mai’s office at 646-888-4226.